Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.54
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
July 18, 2022
Via
Benzinga
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
July 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
July 05, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
June 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
June 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
June 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
June 08, 2022
Moderna tested a bivalent booster, which targets two Covid strains in one shot.
Via
Investor's Business Daily
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Current Report: Takeda Pharmaceutical
May 18, 2022
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.
Via
Talk Markets
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
April 21, 2022
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Via
InvestorPlace
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
April 18, 2022
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
April 13, 2022
Via
Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Exposures
COVID-19
Takeda Announces Completion of Acquisition of Own Shares
April 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
April 12, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.